Physician

Alberto Pinzon Ardila, MD

According to 2025 Medicare claims, Alberto Ardila, MD (NPI: 1154643120) practices epileptologists in the Miami-Miami Beach-Kendall, FL market, with the plurality of this provider's patient population coming from Miami-Dade, FL. This provider's primary affiliated billing organization is NEUROSCIENCE CONSULTANTS LLP (NPI: 1346217452; TIN: 542107535) and primary practice location at 33176-2306.

Ardila's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 423 traditional Medicare patients, billed 4,603 HCPCS/CPT codes, and received $169,829 in Medicare payments. The top billing code was 95720 (Measurement of brain wave activity with video (veeg), 12-26 hours with review and report by health care professional). Part D data shows 2,602 prescription claims across 252 beneficiaries totaling $2,078,668 in drug costs, led by Epidiolex (Cannabidiol (Cbd)). 2023 DME data shows 11 claims. Open Payments data shows 260 records totaling $41,254. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has risen steadily, from $114,230 to $169,829. Similarly, Part D prescription costs have moved sharply higher in recent years, from $315,651 to $2,078,668. In contrast, DME billing represents a smaller volume and moved up and down with repeated peaks and valleys, starting at $1,164 and ending at $1,815.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	477	942	$114,230
2016	437	807	$102,703
2017	424	839	$112,246
2018	491	1,382	$137,636
2019	454	1,465	$186,284
2020	424	1,897	$124,624
2021	543	2,272	$154,972
2022	600	2,094	$155,961
2023	469	3,158	$147,306
2024	423	4,603	$169,829

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	138	1,338	$315,651
2016	134	1,523	$409,719
2017	146	1,542	$448,751
2018	159	1,517	$485,705
2019	178	1,722	$708,088
2020	195	1,895	$820,265
2021	213	2,193	$1,001,698
2022	226	2,391	$1,412,064
2023	233	2,686	$1,618,145
2024	252	2,602	$2,078,668

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	N/R	N/R	N/R
2016	N/R	N/R	N/R
2017	N/R	12	$643
2018	N/R	N/R	N/R
2019	N/R	N/R	N/R
2020	N/R	N/R	N/R
2021	N/R	N/R	N/R
2022	N/R	16	$591
2023	N/R	11	$297
2024	N/R	N/R	N/R

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
95720	Measurement of brain wave activity with video (veeg), 12-26 hours with review and report by health care professional	63	153	$174
99222	Initial hospital care with straightforward or low-level medical decision making, if using time, at least 55 minutes	88	93	$109
99214	Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more	183	495	$96
95819	Measurement of brain wave activity (eeg), awake and asleep	159	181	$45
G2211	Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's	165	347	$14

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Epidiolex	Cannabidiol (Cbd)	168	5,239	$858,773
Fintepla	Fenfluramine Hcl	15	450	$238,053
Aptiom	Eslicarbazepine Acetate	60	2,076	$137,840
Onfi	Clobazam	19	745	$98,461
Briviact	Brivaracetam	40	1,166	$73,166

Top 5 DME services in 2024

No connected or detailed DME service-level records for 2024.

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	258	$25,263	UCB, Inc.
Research Payments	Reported research-related payment or transfer-of-value amount.	2	$15,991	JAZZ PHARMACEUTICALS INC.
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Alberto Pinzon Ardila, MD?

Tedicare shows public-source Medicare data for Alberto Pinzon Ardila, MD (NPI 1154643120), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Alberto Pinzon Ardila, MD have ACO affiliation data?

No ACO affiliation record is shown in the available Tedicare data for this profile.

What billing organization is linked to Alberto Pinzon Ardila, MD?

Alberto Pinzon Ardila, MD is linked to NEUROSCIENCE CONSULTANTS LLP (billing NPI 1346217452) in the available physician profile data.

Does Alberto Pinzon Ardila, MD have Open Payments data?

Alberto Pinzon Ardila, MD has 260 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.